Transplantation of liver grafts from donation after cardiac death (DCD) is limited. To identify barriers of DCD liver utilization, all active US liver transplant centers (n 5 138) were surveyed, and the responses were compared with the United Network for Organ Sharing (UNOS) data. In total, 74 (54%) centers responded, and diversity in attitudes was observed, with many not using organ and/or recipient prognostic variables defined in prior studies and UNOS data analysis. Most centers (74%) believed lack of a system allowing a timely retransplant is a barrier to utilization. UNOS data demonstrated worse 1-and 5-year patient survival (PS) and graft survival (GS) in DCD (PS, 86% and 64%; GS, 82% and 59%, respectively) versus donation after brain death (DBD) recipients (PS, 90% and 71%; GS, 88% and 69%, respectively). Donor alanine aminotransferase (ALT), recipient Model for End-Stage Liver Disease (MELD), and cold ischemia time (CIT) significantly impacted DCD outcomes to a greater extent than DBD outcomes. At 3 years, relisting and retransplant rates were 7.9% and 4.6% higher in DCD recipients. To optimize outcome, our data support the use of DCD liver grafts with CIT <6-8 hours in patients with MELD £ 20. In conclusion, standardization of donor and recipient criteria, defining the impact of ischemic cholangiopathy, addressing donor hospital policies, and developing a strategy for timely retransplant may help to expand the use of these organs.
The successful application of liver transplantation for the definitive treatment of patients with end-stage liver disease is limited by the number of available allografts. In the United States, a high rate of removal from the waiting list reaching 20% or more in many regions (1) has resulted in the increased use of extended criteria grafts, with grafts from donation after cardiac death (DCD) donors having a large potential for increasing the donor supply.
The warm ischemia time (WIT) during the donor agonal phase accounts for the increased incidence of primary nonfunction (PNF; 3%-7%) (2) (3) (4) and ischemic cholangiopathy (IC; 15%-38%) (5) (6) (7) (8) (9) associated with DCD grafts, (10) tempering the initial enthusiasm for these organs. However, single-center reports documenting good patient and graft outcomes when using select donor and recipient criteria, (11) (12) (13) as well as a review of 3 eras of transplantation showing improved outcomes with the identification of selection variables, have renewed the initial enthusiasm.
Despite reports of successful use of DCD livers, many centers have never used or have stopped using DCD hepatic allografts. With the high rate of removal from the liver transplant waiting list, it is important to examine center attitudes about these organs in order to address their concerns and develop strategies for the most effective use of DCD livers. At present, little is known about US transplant centers' attitudes, practices, and perceived challenges to the use of DCD liver transplantation.
The primary objective of the study was to explore center practices regarding transplantation using DCD livers and to compare the attitudes with actual results using data from United Network for Organ Sharing (UNOS). A secondary objective is to identify barriers to the use of these organs.
Patients and Methods

PART I: CENTER PRACTICES AND ATTITUDES ABOUT THE USE OF LIVERS FROM DCD DONORS
The study was approved by the Health Science Campus Institutional Review Board of the University of Southern California. The American Society of Transplant Surgeons (ASTS) Scientific Studies Committee created a 40-question survey addressing practices and attitudes about DCD livers. Practices were explored through questions about prior and current use of DCD livers, definition of WIT, acceptance criteria (WIT, donor and recipient age, cold ischemia time [CIT] , Model for End-Stage Liver Disease [MELD] score, single versus combined liver/kidney transplant, recipient disease etiology), choice of preservation solution, use of thrombolytics, use of biopsies, donor hospital policies, and distance and mode of travel to donor hospital. Perceptions about complications were explored through questions about estimated rates of PNF and IC, relisting criteria, requests for MELD exceptions, response to MELD exception requests, and deaths while awaiting retransplant. Centers were questioned regarding their attitudes about MELD exceptions for IC, reinstating original MELD score for patients with IC, adequacy of the current system for rescuing patients with IC, and perceived barriers to the use of DCD livers (Supporting Table 1 ).
The survey was sent to the 138 active liver transplant centers in the United States in 2014. In total, 74 centers completed the survey. When there were multiple responders from a center, 2 members of the ASTS Scientific Studies Committee chose to use the most senior surgeon's response. All survey data were collected and summarized with frequencies and percentages.
The 74 centers represented all of the regions, with 6, 7, 8, 12, 10, 1, 8, 10, 2, 6, and 4 responses representing regions 1-11, respectively. A total of 7 of the 10 liver transplant centers that performed the highest volume of transplants responded to the survey.
In total, 69 of the 74 (93%) centers answered the question about the estimated percentage of transplants that were performed using DCD livers. Reported estimates ranged from 0% to 30%. In region 1, usage varied from 0.5% to 10%; in region 2, the variation was 0%-5%. Region 3 usage was 0%-20%, and regions 4, 5, 7, and 10 varied from 0% to 15%. The 1 center in region 6 reported 30%; region 8 reported 0%-20%; region 9 reported 0%-7%; and region 11 reported 0%-4%.
PART II: ANALYSIS OF UNOS DATA FOR DCD LIVER TRANSPLANTATION
Selecting a corresponding time period to the survey, data for all whole-liver adult donor to adult recipient (age 18 years) transplants performed from January 1, 2009 through June 30, 2014 were obtained from UNOS, with a data cutoff of September 5, 2014 . The following data were included: donor and recipient age, donor body mass index (BMI), WIT, CIT, final donor hepatic chemistries, calculated recipient MELD, patient and graft outcomes, relisting and retransplantation data. Transplants with CIT > 3 standard deviation or 16 hours and retransplants were excluded.
The UNOS data were analyzed to identify prognostic factors associated with DCD versus donation after brain death (DBD) grafts. The purpose was to correlate these factors with responses to survey questions regarding center acceptance criteria. Relisting and retransplant data were analyzed to correlate with survey-reported estimates of PNF and IC to determine if these estimates were translating into higher retransplant rates. Finally, outcomes and effects on outcomes using selected criteria were examined for the risk/benefit ratio of using DCD organs and were examined to determine what strategies could be implemented to address the concerns raised in the survey.
Analysis of Patient Survival and Graft Survival and the Impact of Prognostic Factors
Outcomes for DCD or DBD transplants were compared. Patient survival (PS) was defined as time from transplant to time of death or last follow-up date for surviving patients. Graft survival (GS) was defined as time from transplant to retransplant or death. Patients with follow-up > 5 years without an event of interest were censored at 5 years. PS and GS rates for DCD and DBD were calculated by using the product-limit method with Greenwood standard errors (SEs). Univariate Cox proportional hazard models were used to examine whether there was a significant difference in PS or GS between DCD and DBD patients.
Univariate and multivariate Cox proportional hazards models were constructed to examine the association between PS and GS with baseline factors including recipient age, recipient MELD, donor age, donor BMI, CIT, donor bilirubin, donor alanine aminotransferase (ALT), and donor aspartate aminotransferase (AST). The association between these factors and outcomes (PS or GS) was first assessed for DCD transplants and DBD transplants separately. Then, in order to investigate whether any of these factors impacted the outcomes of DCD versus DBD recipients differently, the interaction effect between each factor and donor type was examined by analyzing the DCD and DBD transplant data together.
For the test of interaction, each factor was examined either independently from the other factors or after controlling for the remaining factors. If there was a significant interaction between this factor and donor type, then that would indicate that this factor affected outcomes of 1 group of patients significantly more than the other group.
Analysis of Incidence of Relisting and Incidence of Retransplant
Cumulative incidence of relisting and retransplant was compared between the DCD and DBD groups. For the cumulative incidence of relisting, the event of interest was the first relisting, with death as the competing event. Eight retransplanted patients had an unknown relisting date, and for those patients, the retransplant date was used as the relisting date. Patients who died without being relisted were considered as having the competing event of death. For the cumulative incidence of retransplant, the first retransplant was the event of interest, with death as the competing event. Patients with retransplant and death occurring on the same day were treated as having a retransplant. Patients who did not experience either the primary event or the competing event were censored. Gray's test was used to assess the difference between cumulative incidence functions of DCD versus DBD patients.
Results
PART I
Of the 74 centers, 57 (77%) and 17 (23%) answered "yes" and "never or stopped using," respectively, to the question of whether or not they accept DCD livers meeting Maastricht class 3 criteria. Of the 57 centers that accept DCD organs, 27 accept local and imports, while 30 only accept local.
The responses of 65 centers, including 57 who responded that they were currently using, and an additional 8 who had used but stopped using DCD livers were further explored. A diversity in definition of WIT, maximum acceptable CIT, donor age, and recipient MELD were observed across centers. Of these, 33 (51%) centers defined WIT as starting with extubation and ending with cross clamp and cold perfusion; 32 (49%) centers defined WIT as starting with specific blood pressure and/or oxygen saturation and ending with cross clamp and cold perfusion. Each center was asked to provide the maximum acceptable WIT based on their own definition of WIT; the reported maximum acceptable times were 25 minutes (29%), 30 minutes (66%), 35 minutes (2%), and 40 minutes (3%). The maximum acceptable CIT ranged from <6 hours (37%), 8 hours (42%), 10 hours (11%), to up to 12 hours (6%); 3 (5%) centers had no maximum CIT. The maximum accepted donor age varied from <30 to < 60 years. Maximum acceptable age was 40 (31%), 50 (55%), 60 years (9%), and 3 (5%) centers have no maximum donor age. Maximum BMI varied from <30 kg/ m 2 (31%) and <35 kg/m 2 (26%) to < 40 kg/m 2 (9%), with 22 (34%) centers having no maximum. Maximum calculated MELD for patients who are candidates for DCD livers are presented in Fig. 1 .
In deciding to pursue DCD donors, 38/65 (58%) centers considered donor hospital policies, with 34 considering the site of extubation and 28 considering the timing of heparin administration. A total of 19 of 61 (31%) responding centers only use DCD organs that are local or can be reached without air travel, and 28/60 (47%) centers consider the cost of travel. Of 64 centers that responded, 42 (66%) centers consider the potential duration of the agonal phase prior to dispatching a donor team.
Of the 65 centers, 46 (71%) do not accept DCD livers procured by other teams and 9 (14%) additional centers only accept livers procured by donor surgeons whom they know. Regarding preservation solutions, 13 (20%) centers use Custodiol histidine tryptophan ketoglutarate (HTK), 40 (62%) use University of Wisconsin, and 12 (18%) use whatever the procurement team is using. Of the 40 centers that reported > 0%-10% DCD usage, 33 reported a preservation solution preference including 7 of 33 (21%) preferring HTK. Of the 8 centers reporting > 10% usage, 7 reported a preference including 4 (57%) preferring HTK. There are 36 (55%) centers that do not use DCD grafts for combined liver/ kidney transplantation, and only 7 (11%) centers use DCD livers for retransplants.
A total of 12 of 65 (18%) centers modify their surgical technique with DCD livers, and 15 (23%) routinely perform simultaneous portal venous and hepatic arterial reperfusion. Six (9%) centers modify immunosuppression regimen with either enhancement of baseline immunosuppression (n 5 3), addition of basiliximab (n 5 1), or addition of antithymocyte globulin (n 5 2). A total of 18 (28%) centers routinely obtain a biopsy, 21 (32%) centers use thrombolytics, of which 5 centers use these in the donor flush, 6 on the back table, and 13 in the recipient after portal perfusion. Thirty-six (55%) centers responded that they do not take into consideration the recipient's disease etiology.
The responses showed that centers had large discrepancies in their perceptions about complications. Reasons to relist patients with IC included presence of multiple strictures (n 5 39), lack of response to stenting and dilatation (n 5 53), 1 or more episodes of cholangitis (n 5 40), and elevated hepatic chemistries (n 5 16, all of which had selected an additional reason).
The survey provided insight into centers' attitudes and experience about MELD exceptions for IC. Of the 64 centers responding to the questions about requesting MELD exceptions, 46 (72%) responded that they request MELD exception for IC, 7 (11%) responded no, and 11 (17%) responded not applicable. Of the 46 centers that requested MELD exception, 63% had been granted an exception, whereas 11% responded that they had not, and 26% responded not applicable or did not know if exception had been granted. A total of 14 of 46 (30%) centers responded that they had deaths in recipients of DCD livers while awaiting retransplant, and 11 (24%) responded yes to the question that there were deaths in patients for whom a MELD exception had been requested and denied.
Of 72 centers responding to questions about barriers to the use of DCD livers, 44 (61%) centers feel that patients with IC should routinely receive MELD exception, 52 (72%) feel that the current system is inadequate for obtaining a timely retransplant, and 53 (74%) feel the absence of a pathway to rescue recipients with IC is a barrier to expanding the use of DCD livers.
A total of 16 centers with a self-reported 0% recent usage of DCD transplants included 5 centers that experienced an estimate of >10% IC. Ten centers that performed >5%-10% DCD transplants included 2 centers reporting > 10% IC. Of the 30 centers performing more than 10% DCD liver transplants, only 1 reported > 10% IC. There appears to be a trend of lower self-reporting rate of IC in higher-volume centers that requires further exploration to determine the impact on the individual centers.
PART II
Review of UNOS data identified 1357 and 25,562 adult recipients of a primary transplant using a whole liver from DCD and DBD donors respectively. Table  1 describes these donor and recipient variables.
The 1-to 5-year PS and GS rates are presented in Fig. 4 . There were significant differences in the PS and GSs between the DCD recipients versus the DBD recipients. The 1-, 3-, and 5-year PS rates were 86%, NOTE: Data are given as n (%). P value from chi-square test. *Difference in distribution between DBD and DCD groups was not only statistically but clinically significant. A clinically significant difference of 10% was found between the 2 groups of patients.
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76%, and 64% for DCD liver recipients, and 90%, 80%, and 71% for DBD liver recipients (P < 0.001). The 1-, 3-, and 5-year GS rates were 82%, 71%, and 59% for DCD liver recipients, and 88%, 78%, and 69% for DBD liver recipients (P < 0.001). Hence, DCD patients had both significantly worse PS and GS than DBD patients. Additionally, Tables 2 and 3 confirm that the decreased survival exists in all regions. The worse outcomes of DCD patients compared with DBD patients were further demonstrated by the significantly higher relisting and retransplant rates of DCD recipients compared with DBD recipients (Fig.  5) . At 1 year after the initial transplant, the cumulative incidence of relisting at 1 year was 10.4% for DCD liver recipients compared with 4.2% for DBD recipients; the cumulative incidence of retransplant at 1 year was 5.6% for DCD recipients and 2.5% of DBD recipients. By the end of the third year, 13.2% relisted and 7.9% were retransplanted in the DCD group compared with 5.3% and 3.3% in the DBD group. Both the cumulative incidence of relisting and of retransplant were significantly higher for the DCD recipients than for the DBD recipients (P < 0.001). In the DCD group, 32/154 (21%) relisted patients died without a retransplant; in the DBD group, 279/1201 (23%) of relisted patients died without a transplant.
The associations between the factors and PS are presented in Table 4 . Controlling for the other variables, donor ALT (P 5 0.004) had a significant interaction with donor type, and the interaction effect between MELD at time of transplant and donor type was marginally significant (P 5 0.06; Table 4 ). These results suggested that though it was the case that higher MELD at transplant was significantly associated with worse PS in both DCD and DBD patients, the association between higher MELD and worse survival was more dramatic for DCD patients.
In addition, the data identified ALT as an important prognostic factor for DCD grafts: recipients of DCD organs with ALT > 100 had significantly worse survival compared with recipients with ALT 100. In contrast, PS of recipients of DBD organs with ALT > 100 was at least comparable to those with ALT 100. The meaning of this finding in DBD grafts requires confirmation and further exploration. As the value is intended to be the preterminal value, the prior values are unknown, and therefore, the trend of the hepatic chemistries is unknown. The associations between the factors and GS are presented in Table 5 . After controlling for the other variables, there was a significant interaction between donor type and donor ALT (P 5 0.02), as well as between donor type and MELD at transplant (P 5 0.02; Table 5 ).
These results suggested similar conclusions on GS as PS presented above. The association between higher MELD with worse GS was significantly more dramatic for DCD recipients than for DBD recipients. Besides donor ALT and MELD at transplant, CIT trended to significance in the multivariate model (P 5 0.08; Table 5 ), indicating that higher CIT tended to lead to worse GS in DCD recipients than in DBD recipients. Results were largely similar when each factor was assessed independently from other variables.
Examining the percent of MELD exceptions by transplant type, 40% of DBD transplants and 46% of DCD transplants were performed in patients with MELD exceptions (P < 0.001).
COMPARISON OF SURVEY AND UNOS DATA
The survey pointed out the diversity of opinions regarding the use of DCD hepatic allografts. Not only was the definition of WIT varied among the centers, but there were variations pertaining to donor selection criteria as well as recipient selection. The UNOS data demonstrated that the most significant variables in donor selection include CIT and recipient MELD scores. However, many of the centers (n 5 14, 22%) accept CIT 10 hours or more or do not have a maximum time. In addition, 45 (69%) centers accept DCD livers for recipients with a maximum MELD of 35 or do not have a maximum MELD.
Although the UNOS data showed a 4% difference in PS and a 7% difference in GS by 3 years, these results can be impacted upon by selecting low-risk recipients and minimizing CIT. By selecting recipients with calculated MELD scores of 20, 3-year differences in PS and GS were decreased to 2% and 4% respectively. By maintaining the CIT 6 hours, the difference in 3-year GS was decreased to 4%. 
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The self-reporting of estimates of PNF were generally low, whereas the self-reporting of IC was varied, with estimates from 0% to > 50%. A total of 32 of 64 (50%) centers reported estimates of IC to be >10%-20%. The relisting and retransplant rates were significantly higher for DCD grafts compared with DBD grafts; by 3 years, the cumulative incidence for relisting for DCD grafts was 7.9% higher, and for retransplant approximately 4.6% higher. Because many centers reported high rates of IC, with many above 10%-20%, there are questions raised as to what are the relisting criteria for patients with IC, and what is the actual impact of IC on hepatic function and morbidity that would lead to relisting and retransplant. The higher estimates of IC warrant further exploration because they did not correlate with the differences in cumulative rates of relisting and retransplantation.
Although 55% of centers surveyed responded that they do not consider the disease etiology in using DCD organs, UNOS data demonstrated that there was a significantly higher use of DCD grafts with MELD exception. This requires further exploration to determine if in fact, disease etiology, such as HCC, may have an effect on usage. Furthermore, analysis of the UNOS data did not demonstrate any interaction between HCV and DCD outcomes (data not shown). NOTE: The multivariate model also controlled for donor bilirubin and donor AST. *P value testing interaction between each independent variable and DBD/DCD in a multivariate model. † Trend test.
Discussion
The initial excitement for DCD hepatic allografts was tempered by an increase in biliary complications, decreased GS, higher retransplant rate, and increase in acute kidney injury associated with long cold times and older recipient age. (2, 5, 12, (14) (15) (16) (17) However, the identification of and use of prognostic factors has led to encouraging results when DCD livers are used in lowrisk recipients using younger livers (<50 years of age) and maintaining short CIT (<6 hours). (14, (17) (18) (19) Considering the variability of DCD liver utilization by OPOs across the nation that ranges from as low as 2% to as high as 14%, we were interested in transplant surgeons' perceptions, practices, and actual uses, compared with UNOS data that may explain the variability seen. (20) Although only approximately 50% of centers responded to the survey, the responding centers represented all regions and included many high-volume centers. Our survey responses confirmed our supposition of lack of uniformity between centers regarding practices and attitudes about DCD livers. The self-reported estimates of PNF were generally low, whereas the rates for IC were extremely variable, with many centers reporting high rates of up to 50%. Our survey results indicate a slightly more liberal WIT and CIT than what is supported in the literature. (21) The maximum acceptable donor age is within reported limits. Interestingly, the survey response for maximum acceptable CIT and maximum MELD revealed that many centers self-reported upper limits, or lack of an upper limit, that are contrary to the findings reported in the literature, and interestingly, contrary to the results of the UNOS data. The self-reported rates of IC were varied, but for the most part, in line with what has been reported. (2) The UNOS data analysis reveals the lower PS and GS rates seen in DCD donors, along with higher relisting and repeat transplant rates, which is in line with prior reports. (14, 15, 17) Remarkably, we found that the finding of an elevated ALT in DCD donors was associated with poor PS, and may be explained by hypothesizing that prerecovery injury compounded with WIT would result in poor posttransplant function and outcomes. In 20-year follow-up, Yamamoto et al. found that post-liver transplant peak ALT was an independent predictive factor for GS in the DCD group. (8) The reported ALT and AST values are not representative of the entire hospital course of the donor. Therefore, the use of these values requires further exploration. The multivariate analysis did confirm that minimizing CIT to <8 hours in DCD donors, consideration of the donor hepatic chemistries, and using DCD livers in patients with lower calculated MELD scores can maximize the PS and GS when using these grafts.
Although it is understandable that higher MELD patients' overall survival can be improved when using a DCD liver graft compared with mortality on the waiting list, (22) data from the current study support using DCD liver grafts to lower MELD 20 patients to improve the outcomes with these grafts.
The Mayo Clinic report revealed improving outcomes in the more recent eras of 2007-2014, with a suggestion that this improvement has resulted from modification of donor and recipient selection, including patients with lower MELD scores. (23) A recent analysis of outcomes in patients who underwent relisting and retransplant demonstrated that PS was no worse for primary DCD than for primary DBD recipients. This therefore suggests, that despite relisting and transplanting, the DCD patients are not as sick as relisted DBD recipients that have vascular, biliary, and other reasons for retransplant. (24) This is actually contrary to many transplant surgeons' perceptions. Our data did not cover any specific era in the Mayo report. However, examining 2011 through 2013, the 1-year PS differences were small and confirmed the improved outcomes in the Mayo report. Also contrary to some surgeons' perceptions, a report by Maduka et al. found that DCD recipients relisted for transplant have lower wait-list mortalities than DBD retransplant candidates. They found that patients who received MELD exception points had a higher rate of retransplantation and were less likely to be removed from the waiting list for death or clinical deterioration. They also found variability in requesting MELD exceptions, as well as receiving MELD exception points. (25) This later finding matches our survey wherein approximately 11% have not asked for an exception or been granted an exception.
We can extrapolate why there is a variability seen in our survey and differences in the outcomes seen by the UNOS data registry. We believe there are practice differences across our country, possibly due to a variety of factors, which can include prior experience, variability in donor hospital policies, impact of cost and travel for a DCD donor that may not become a donor, perceived rates of nonfunction and IC, and concerns regarding the ability to retransplant in a timely fashion. The UNOS data pertaining to actual cumulative risk of relisting and retransplant is reassuring, in that the higher rates for DCD did not translate into exorbitant retransplant rates of 7.9% versus 3.3% for DBD. Almost three-quarters of the centers reported that they do not feel that the current system is adequate for obtaining a timely retransplant and that the absence of a pathway to rescue recipients with DCD-related IC is a barrier to expanding the use of DCD livers. The self-reporting of indications for transplant in the UNOS database reveals multiple indications for many patients and indications that are difficult to interpret. Because of the difficulty of analyzing and interpreting these data, it was challenging to correlate the perceptions of the centers with the actual indications. It will be important to investigate the variability of IC and to determine the exact impact of IC on morbidity and mortality, especially with the use of thrombolytics. Furthermore, it is important to develop a consensus about uniform relisting criteria that reflects the morbidity of IC that justifies a MELD score increase. Given the approximate 20% rate (and > 25% in some regions) of removal from the waiting list for death or the designation "too sick," it seems imperative to develop strategies to increase utilization of these organs. (20, 26) The UNOS data showed that the PS and GS differences between DCD and DBD grafts can be reduced by considering the identified prognostic factors, and therefore, uniform selection criteria with strategies to decrease the CIT and identify appropriate patient populations can be expected to improve outcomes and alleviate center concerns about IC and PS. This is in congruence with work by the British Transplant Society, which compiled a working party providing guidelines on transplantation from DCD donors, and a statement of recommendations which included use of low viscosity solution for cold flush of the aorta, keeping CIT to <8 hours, the ideal DCD donor age of <50 years old, functional WIT of <20 minutes, <10% steatosis, avoiding DCD grafts for retransplantation, and using younger recipients <60 years of age.
We found that donor hospital policies impacted the decision to dispatch a donor procurement team for more than half the centers. Strategies to create more favorable policies at donor centers can potentially increase the use of these organs. Although more challenging, education in donor hospitals is important to allow for standardization of policies pertaining to timing of anticoagulation and the site of extubation.
Our findings confirm that centers' attitudes and perceptions of DCD hepatic allografts impact their practices, whereas many of their criteria and perceptions are not confirmed by UNOS data. Our data support the use of DCD livers with short CIT in patients with low MELD scores. Potential future strategies to improve upon and implement include uniform donor and recipient selection criteria; facilitation of rapid placement and implantation of these organs; and development of a grading system for IC and uniform relisting criteria. Uniform relisting criteria can guide appropriate MELD exception scores to facilitate retransplantation in patients meeting accepted criteria. New understanding of ischemia/reperfusion injury and new technologies for organ preservation (such as ex vivo normothermic machine preservation), which are currently being studied, may improve the quality of these organs. Although the selection criteria may narrow the differences in PS and GS substantially, it is possible that new technologies may further contribute and eradicate the differences. (27, 28) 
